The global drug discovery services market size is projected to garner significant growth from 2023 to 2033. According to the research report, the global market is anticipated to surpass a valuation of US$ 19.7 billion in 2023. It is likely to hit a valuation of US$ 76.5 billion by 2033. The market is projected to thrive at a CAGR of 14.5% from 2023 to 2033.
The demand for drugs is swelling to treat chronic disorders and unmet medical needs. The developing market for pharmaceuticals is augmenting the market share for drug discovery services. Market growth is likely to be amplified by technological advancements. Additionally, there has been a rise in the use of innovative discovery methods in recent years. For instance, mass spectrometry is a proteomics technique used to uncover every stage of oncology drug discovery.
Empower your decisions with data-driven insights from our Sample Report – Get It Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-14258
Rising drug distribution is a result of escalating generic medicine demand and an increase in patent expirations. Demand for drug discovery services is increasing due to expanding healthcare sector and the rising demand for generic drugs. The aging population, as well as technological advancements in drug discovery services, aid the market’s rapid expansion.
Discovering and developing new drugs can incur huge costs and time. The need for specialization in different scientific fields grows as drug research becomes more difficult. Toxicology, medicinal chemistry, pharmacology, and formulation development experts are typically involved in the development of new medications. Research organizations and pharmaceutical businesses can cut costs and time by outsourcing these services. Without making significant expenditures, the market for outsourced drug delivery services offers access to specialized infrastructure and knowledge.
North America is anticipated to dominate global market shares. The drug discovery services industry in the region operates as a free market with transparent trading practices and restrictions on anti-competitive behavior. The market for biosimilars in the United States is growing tremendously as biologics are more expensive in the region.
Key Takeaways from Drug Discovery Services Market:
- In 2022, the global drug discovery services market size stood at US$ 17.5 billion.
- The pharmaceutical companies segment accounted for 42% market share in 2022.
- In terms of market share, the Hit-to-lead identification method is the dominant segment.
- During the projection period, the biological services segment in the market is expected to increase at a high CAGR.
- The oncology segment accounted for an impressive 39.7% market share in 2022.
- North America accounted for a massive 35.2% market share in 2022.
Recent Developments Observed by FMI:
- Genentech announced in January 2023 that it had been granted Priority Review and Fast Track designation for Glofitamab. To treat adult patients with refractory or relapsing LBCL, the medication, a new bispecific antibody, activates immune system T-cells.
- Brexpiprazole, an atypical antipsychotic supplement NDA authorized for schizophrenia, was released in January 2023 under FDA Priority Review. Brexpiprazole was developed by H. Lundbeck A/S and Otsuka Pharmaceuticals.
- The FDA approved UCB’s Rozanolixizumab for additional Phase III research in January 2023.
- Harm Reduction Therapeutics announced about RiVive in December 2022. As the FDA accepted and awarded Priority for Review to their new drug application. The product is an over-the-counter nasal spray form of naloxone.
Elevate Your Understanding With Our Insightful Methodology Now! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14258
Key Players in the Market:
- Laboratory Corporation of America Holdings
- Charles River Laboratories International Inc.
- Genscript Biotech Corporation
- Thermo Fisher Scientific Inc.
- Pharmaron Beijing Co. Ltd.
- Evotec SE
- Eurofins Scientific SE
- Pharmaceutical Product Development Inc.
- Piramal Enterprise Limited
- Syngene International Limited
Market Segmentation:
By Process:
- Target Selection
- Target Validation
- Hit-to-lead identification
- Lead Optimization
- Candidate Validation
By Type:
- Chemistry Services
- Biology Services
By Drug Type:
- Small Molecule Drugs
- Biologics Drugs
By Therapeutic Area:
- Neurology
- Infectious and Immune Systems Diseases
- Digestive System Diseases
- Oncology
- Other Therapeutic Areas
By End User:
- Pharmaceutical & Biotechnology Companies
- Academic Institutes
- Manufacturing
- Other End Users
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- The Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
